Pharmanutra SpA
MIL:PHN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pharmanutra SpA
MIL:PHN
|
IT |
|
P
|
PCC Exol SA
WSE:PCX
|
PL |
|
W
|
Wayfair Inc
F:1WF
|
US |
Intrinsic Value
The intrinsic value of Pharmanutra SpA (PHN) under the Base Case is 58.45 EUR per share.
Compared with the current market price of 71.1 EUR, the stock appears
Overvalued by 18% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Pharmanutra SpA Does
Pharmanutra SpA develops and sells nutraceutical and medical food products, with a strong focus on iron-based supplements and other nutrition items used to support specific health needs. Its products are sold through pharmacies, doctors, and other healthcare channels, and some are used in clinical settings where patients need targeted nutritional support.
- Headquarters
- Italy IT
- Employees
- 128
- IPO date
- Jul 18, 2017
Pharmanutra has a narrow economic moat
Pharmanutra SpA has a narrow economic moat, offering limited protection against competitors and some ability to sustain profitability.
Read the full moat analysis
Revenue & Expenses Breakdown
Pharmanutra SpA
Earnings Waterfall
Pharmanutra SpA
The intrinsic value for Pharmanutra SpA (PHN) under the Base Case is 58.45 EUR.
Compared with the current market price of 71.1 EUR, the stock appears Overvalued by 18% .